Codexis Reports 2018 Fourth Quarter and Full Year Financial Results
February 26, 2019 16:05 ET
|
Codexis, Inc.
2018 revenues of $61 million include a 50% increase in R&D revenue Introduces 2019 financial guidance Conference call begins at 4:30 pm Eastern time todayAccompanying slide presentation available...
Codexis Names Laurie Heilmann Senior Vice President of Business Development and Marketing
February 25, 2019 07:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of...
Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26
February 19, 2019 07:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial...
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
February 14, 2019 07:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain...
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
February 06, 2019 07:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a...
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
February 04, 2019 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a...
Codexis Reports Third Quarter 2018 Financial Results
November 08, 2018 16:05 ET
|
Codexis, Inc.
Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers Conference call begins at 4:30 p.m. Eastern time today ...
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
November 08, 2018 07:00 ET
|
Codexis, Inc.
CDX-6114 meets safety and tolerability endpoints REDWOOD CITY, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces top-line...
Codexis to Present at Two Investment Conferences in November
November 07, 2018 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment...
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
July 09, 2018 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase...